Kyverna Therapeutics (Nasdaq: KYTX) signs ElevateBio deal for miv-cel
Rhea-AI Filing Summary
Kyverna Therapeutics entered a new Clinical and Commercial Supply Agreement with ElevateBio that replaces their prior development and manufacturing arrangement for miv-cel, its autologous CD19-directed CAR T-cell therapy for autoimmune diseases. ElevateBio will provide development, clinical and commercial manufacturing under statements of work, and Kyverna agreed to order at least certain minimum quantities of miv-cel in specified years and after regulatory approvals.
The agreement runs for an initial term of five years, then automatically renews for successive one-year periods, and includes annual price and fee adjustments tied to the Producer Price Index for Pharmaceutical Preparation Manufacturing, along with customary quality, audit and confidentiality provisions. A joint press release notes ElevateBio’s clinical manufacturing success rate of more than 98% for miv-cel and states that Kyverna remains on track to complete its rolling Biologics License Application submission for stiff person syndrome in the fourth quarter of 2026, supporting potential launches in stiff person syndrome and generalized myasthenia gravis and other ongoing studies.
Positive
- None.
Negative
- None.
Filing Explained
The agreement creates minimum-order obligations, but pricing, scope, and full economics remain pending statements of work and the September 30, 2026 quarterly filing.
Kyverna Therapeutics reports that it signed a new supply agreement with ElevateBio on July 23, 2026, replacing the prior arrangement and creating minimum-order obligations for miv-cel in specified years and, in some cases, after regulatory approval. The agreement provides for development and manufacturing services, but the filing does not say that any commercial supply has been delivered.
The joint release describes the arrangement as securing flexible, scalable commercial supply, but the 8-K says product prices, service fees, expenses, and work scopes will be set in future statements of work; the filing does not quantify the minimum quantities or state a total dollar commitment.
The agreement has a five-year initial term with potential one-year renewals, while its full text is to be filed with the Form 10-Q for the quarter ending September 30, 2026; Kyverna also intends to seek confidential treatment for some terms.
8-K Event Classification
Key Figures
Key Terms
Clinical and Commercial Supply Agreement regulatory
Biologics License Application regulatory
autologous CD19-directed CAR T-cell therapy medical
Producer Price Index financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What agreement did Kyverna Therapeutics (KYTX) sign with ElevateBio?
How long is the Kyverna (KYTX) and ElevateBio supply agreement in effect?
Which product is covered by the Kyverna (KYTX) manufacturing agreement?
When does Kyverna Therapeutics (KYTX) expect to finish its miv-cel BLA for SPS?
How does ElevateBio’s performance support Kyverna (KYTX) in this deal?
How are prices set under the Kyverna (KYTX)–ElevateBio supply agreement?
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): |
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction |
(Commission File Number) |
(IRS Employer |
||
|
|
|
|
|
|
||||
|
||||
(Address of Principal Executive Offices) |
|
(Zip Code) |
||
Registrant’s Telephone Number, Including Area Code: |
|
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
|
Trading |
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 1.01 Entry into a Material Definitive Agreement.
As previously disclosed, on July 22, 2023, Kyverna Therapeutics, Inc. (the “Company”) entered into that certain Development and Manufacturing Services Agreement (as amended by Amendment #1 thereto on July 24, 2023, the “Prior Agreement”) with ElevateBio Basecamp, Inc. (“ElevateBio”), pursuant to which ElevateBio has provided the Company with cell manufacturing, release and testing services for the Company’s lead product candidate, mivocabtagene autoleucel, also known as “miv-cel” (the “Product”).
On July 23, 2026, the Company and ElevateBio entered into a Clinical and Commercial Supply Agreement (the “Agreement”), which replaces the Prior Agreement in its entirety and pursuant to which, among other things, ElevateBio agreed to provide the Company with development and manufacturing services for the clinical and commercial supply of the Product, as shall be set forth in one or more statements of work to be executed by the parties pursuant to the Agreement. Under the Agreement, the Company agreed to order at least certain minimum quantities of the Product in certain calendar years and/or following receipt of approval of the Product by government regulatory authorities, including the U.S. Food and Drug Administration.
The prices of the Product and the fees and expenses for the services performed by ElevateBio pursuant to the Agreement, which will be set forth in the applicable statement of work, are subject to an annual adjustment based on inflation up to a maximum percentage amount calculated using data from the Producer Price Index (“PPI”) for Pharmaceutical Preparation Manufacturing.
The Agreement also includes customary acceptance, warranty, quality, testing and inspection, audit, access to information, and confidentiality terms and conditions.
The Agreement has an initial term of five years unless terminated earlier in accordance with its terms and conditions, and automatically extends for successive one-year renewal periods unless terminated by either party with certain advance notice and upon certain conditions or by either party upon an uncured material breach by the other party.
The foregoing description of the Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Agreement, which will be filed with the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ending September 30, 2026, and which is incorporated herein by reference. The Company intends to seek confidential treatment for certain terms of the Agreement in connection with the filing of such agreement in accordance with the procedures of the Securities and Exchange Commission.
Item 7.01 Regulation FD Disclosure.
On July 27, 2026, the Company and ElevateBio issued a joint press release announcing the entry into the Agreement. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
The information contained in Item 7.01 of this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly provided by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit Number |
|
Description |
99.1 |
|
Joint Press Release issued by Kyverna Therapeutics, Inc. and ElevateBio, dated July 27, 2026. |
104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
KYVERNA THERAPEUTICS, INC. |
|
|
|
|
|
Date: July 27, 2026 |
|
By: |
/s/ Gregory Martini |
|
|
|
Gregory Martini |
|
|
|
Chief Financial Officer |
Exhibit 99.1
|
|
|
Kyverna Therapeutics and ElevateBio Enter into Commercial Manufacturing and Supply Agreement for Miv-cel
New agreement secures flexible and scalable manufacturing to support the U.S. commercial and global clinical supply of miv-cel
EMERYVILLE, Calif., and WALTHAM, Mass., July 27, 2026 -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a late-stage clinical biopharmaceutical company developing cell therapies for patients with autoimmune diseases, and ElevateBio, a technology-driven advanced therapy contract development and manufacturing organization (CDMO), today announced a manufacturing agreement for both U.S. commercial and global clinical supply of miv-cel (mivocabtagene autoleucel), Kyverna’s autologous CD19-directed CAR T-cell therapy.
The new agreement provides Kyverna with flexible and scalable supply of miv-cel, supporting the Company’s potential launches in stiff person syndrome (SPS) and generalized myasthenia gravis (gMG), as well as other ongoing clinical studies. Over the past three years, Kyverna and ElevateBio have built a strong clinical-stage partnership, delivering a track record of success in process development, quality systems, and cell product manufacturing optimization, supporting the SPS Biologics License Application (BLA) and laying the foundation for future growth.
“Kyverna’s highest priority is to bring the transformative potential of miv-cel to patients, and this agreement with ElevateBio further strengthens our commercialization readiness and long-term manufacturing supply as we prepare for launch in stiff person syndrome and future indications,” said Mayo Pujols, Chief Technology Officer of Kyverna. “With ElevateBio’s proven expertise in manufacturing innovation and quality, demonstrated by a clinical manufacturing success rate of more than 98% for miv-cel, as well as their ability to scale production, we’re pleased to continue to advance our partnership.”
Kyverna remains on track to complete the rolling BLA submission for miv-cel in SPS in the fourth quarter of 2026. If approved, miv-cel has the potential to become the first FDA-approved CAR T-cell therapy for an autoimmune disease and the first approved treatment for people living with SPS.
“This agreement affirms ElevateBio’s commitment to the commercial supply of miv-cel and highlights the quality of our partnership with Kyverna,” said Chris Murphy, Chief Executive Officer of ElevateBio. “By combining our technology and manufacturing expertise with Kyverna’s leadership in autoimmune cell therapies, we are well-positioned to deliver reliable supply that supports patients today and growing demand in the years ahead.”
About miv-cel (mivocabtagene autoleucel, KYV-101)
Miv-cel is a fully human, autologous, CD19-targeting CAR T-cell therapy with CD28 co-stimulation, designed for potency and tolerability, which is under investigation for B-cell-driven autoimmune diseases. With a single administration, miv-cel has potential to achieve deep B-cell depletion and immune system reset to deliver durable drug-free, disease-free remission in autoimmune diseases.
About Kyverna Therapeutics
Kyverna Therapeutics, Inc. (Nasdaq: KYTX) is a late-stage clinical biopharmaceutical company focused on liberating autoimmune patients through the curative potential of cell therapy. Kyverna’s lead autologous CD19-targeting CAR T-cell therapy candidate, miv-cel (mivocabtagene autoleucel, KYV-101), has demonstrated the potential to fundamentally change the treatment paradigm across multiple B-cell-driven autoimmune diseases. Kyverna is advancing its potentially first-in-class neuroimmunology franchise with its recently completed registrational trial in stiff person syndrome (SPS) and an ongoing registrational trial for generalized myasthenia gravis. The Company has initiated its rolling Biologics License Application submission for SPS with the FDA. It is also harnessing other KYSA trials and investigator-initiated trials, including in multiple sclerosis and rheumatoid arthritis, to inform the next priority indications. Additionally, its next-generation pipeline includes CAR T-cell therapies deploying novel innovations to improve patient access and experience. For more information, please visit https://kyvernatx.com.
About ElevateBio
ElevateBio is a technology-driven advanced therapy contract development and manufacturing organization (CDMO) powering the creation of life-transforming therapies. The Company helps biopharmaceutical partners design, develop, and manufacture therapies from early discovery through commercialization, combining proprietary gene editing technologies and discovery services, cGMP manufacturing capabilities, and industry-leading expertise to accelerate development across a breadth of therapeutic approaches and modalities. Through continuous investment in automation, AI, and next-generation technologies, ElevateBio delivers the quality, speed, and scale partners need to bring advanced therapies to more patients. For more information, visit www.elevate.bio.
Forward-Looking Statements
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” The words, without limitation, “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these or similar identifying words. Forward-looking statements in this press release include, without limitation, those related to: Kyverna’s next phase of growth and potential long-term growth, including its transition to a commercial-stage organization; any potential FDA approval and commercial launch of miv-cel in SPS; Kyverna’s pipeline opportunities and strategic priorities; Kyverna’s potentially first-in-class neuroimmunology franchise; Kyverna’s rolling BLA SPS submission and expected timeline for completion thereof; the possibility that miv-cel will be the first FDA-approved CAR-T cell
therapy for an autoimmune disease and the first approved treatment for people living with SPS; Kyverna’s potential to advance curative treatments for patients and any anticipated demand therefor; the expected benefits of the manufacturing and supply agreement with ElevateBio, including its ability to provide reliable supply of miv-cel and support Kyverna’s potential launches in SPS, gMG and other ongoing clinical studies, and to scale production and further strengthen Kyverna’s commercialization readiness and long-term manufacturing supply; the quality of ElevateBio’s manufacturing and its partnership with Kyverna ; and miv-cel’s potential to fundamentally change the treatment paradigm across multiple B-cell-driven autoimmune diseases, and to achieve deep B-cell depletion and immune system reset to deliver durable drug-free, disease-free remission in autoimmune diseases. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: uncertainties related to market conditions, the possibility that results from prior clinical trials, named-patient access activities and preclinical studies may not necessarily be predictive of future results; the possibility that the past track records of Kyverna or ElevateBio may not be repeated or indicative of future success; and other factors discussed in the “Risk Factors” section of Kyverna’s most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q that Kyverna has filed or may subsequently file with the U.S. Securities and Exchange Commission. Any forward-looking statements contained in this press release are based on the current expectations of Kyverna’s management team and speak only as of the date hereof, and Kyverna specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
Kyverna Contacts:
Investors: InvestorRelations@kyvernatx.com
Media: media@kyvernatx.com
ElevateBio Contacts:
Investor contact:
Catherine Hu
chu@elevate.bio
Media contact:
DJ Webster
dwebster@elevate.bio